Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASYS in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B
NCT00460850Phase 4Terminated
- Sponsor
- Roche
- Start
- Sep 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated interferon alpha in Chronic Hepatitis B (CHB), sponsored by Roche. Primary endpoint: Normalization of ALT and HBV-DNA <10,000 copies/mL at 96 weeks. Started Sep 2007; status: terminated.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00460850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460850.